Over the course of three decades of study, the deubiquitinase Herpesvirus associated
Ubiquitin-Specific Protease/Ubiquitin-Specific Protease 7 (HAUSP/USP7) has gradually …

As the volume of publications rapidly increases, searching for relevant information from the
literature becomes more challenging. To complement standard search engines such as …

Protein kinase inhibitors are potent anticancer therapeutics. For example, the Bcr-Abl kinase
inhibitor imatinib decreases mortality for chronic myeloid leukemia by 80%, but 22 to 41% of …

Chronic myelogenous leukemia (CML) is a clonal malignancy of hematopoietic stem cells
featured with the fusion protein kinase BCR-ABL. To elicit the mechanism underlying BCR …

Mutations in the drug binding region of BCR-ABL lead to imatinib resistance during the
management of chronic myeloid leukemia (CML). In our study, 62 Philadelphia positive …

Chronic myeloid leukemia (CML) is associated with the Philadelphia chromosome and
distinct BCR:: ABL1 gene transcripts. We assessed the frequencies of these transcripts in …

There is a great demand to introduce new approaches into cancer treatment field due to
incidence of increased breast cancer all over the world. The current study was designed to …

Clinical effectiveness of imatinib mesylate in cancer treatment is compromised by its off-
target cardiotoxicity. In the present study, we have developed physically stable imatinib …

The introduction of tyrosine kinase inhibitors (TKIs) in the treatment of chronic myeloid
leukemia (CML) has significantly increased survival rate and quality of life for patients with …

Resistance toward imatinib (IM) and other BCR/ABL tyrosine kinase inhibitors remains
troublesome in the treatment of advanced stage chronic myeloid leukemia (CML). The aim of …